HLA class I-mediated induction of cell proliferation involves cyclin E- mediated inactivation of Rb function and induction of E2F activity

Journal of Immunology

Volumn 162, Issue 9, 1999, Pages 5351-5358

  Nath, Niharika ^a   Bian, Hong ^a   Reed, Elaine F ^a   Chellappan, Srikumar P ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLIN E; HLA ANTIGEN CLASS 1; OLOMOUCINE; TRANSCRIPTION FACTOR E2F;

ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; GRAFT REJECTION; HLA SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL DIVISION; CELLS, CULTURED; CYCLIN E; CYCLIN-DEPENDENT KINASES; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GROWTH INHIBITORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMIDAZOLES; JURKAT CELLS; KINETIN; PURINES; PYRIDINES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS;

EID: 0033136277     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Norbury, C., and P. Nurse. 1992. Animal cell cycles and their control. Annu. Rev. Biochem. 61:441.
2. Murray, A. W. 1992. Creative blocks: cell cycle checkpoints and feedback controls. Nature 359:599.
3. Murray, A. W., and T. Hunt. 1993. The Cell Cycle: An Introduction. Oxford University Press, Oxford.
4. Kamb, A. 1995. Cell cycle regulators and cancer. Trends Genet. 11:136.
5. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323.
6. Paggi, M. G., A. Baldi, F. Bonetto, and A. Giordano. 1996. Retinoblastoma protein family in cell cycle and cancer: a review. J. Cell. Biochem. 62:418.
7. Pardee, A. B. 1994. Multiple molecular levels of cell cycle regulation. J. Cell. Biochem. 54:375.
8. Ewen, M. E., H. K. Sluss, C. J. Sherr, H. Matsushime, J. Kato, and D. M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487.
9. Sherr, C. J. 1994. The ins and outs of RB: coupling gene expression to the cell cycle clock. Trends Cell. Biol. 4:15.
10. Beijersbergen, R. L., and R. Bernards. 1996. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim. Biophys. Acta 1287:103.
11. 1 checkpoint. Mol. Cell. Biol. 16:6917.
12. Kato, J., H. Matsushime, S. W. Hiebert, M. E. Ewen, and C. J. Sherr. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7:331.
13. Kato, J. Y., M. Matsuoka, D. K. Strom, and C. J. Sherr. 1994. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol. Cell. Biol. 14:2713.
14. Taya, Y. 1997. RB kinases and RB-binding proteins: new points of view. Trends Biochem. Sci. 22:14.
15. Lundberg, A. S., and R. A. Weinberg. 1998. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18:753.
16. Chellappan, S. P., S. Hiebert, M. Mudryj, J. M. Horowitz, and J. R. Nevins. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053.
17. Bagchi, S., R. Weinmann, and P. Raychaudhuri. 1991. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 65:1073.
18. Chittenden, T., D. M. Livingston, and W. G. Kaelin, Jr. 1991. RB associates with an E2F-like, sequence-specific DNA-binding protein. Cold Spring Harbor Symp. Quant. Biol. 56:187.
19. Chellappan, S. P. 1994. The E2F transcription factor: role in cell cycle regulation and differentiation. Mol. Cell. Differ. 2:201.
20. Dyson, N. 1998. The regulation of E2F by pRB-faraily proteins. Genes Dev. 12:2245.
21. Nevins, J. R. 1998. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 9:585.
22. Johnson, D. G., and R. Schneider-Broussard. 1998. Role of E2F in cell cycle control and cancer. Front. Biosci. 3:d447.
23. Shan, B., X. Zhu, P. L. Chen, T. Durfee, Y. Yang, D. Sharp, and W. H. Lee. 1992. Regulation of E2F/cyclin A-containing complex upon retinoic acid-induced differentiation of teratocarcinoma cells. Gene Expression 2:259.
24. Ikeda, M. A., L. Jakoi, and J. R. Nevins. 1996. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc. Natl. Acad. Sci. USA 93:3215.
25. Puri, P. L., L. Cimino, M. Fulco, C. Zimmerman, N. B. La Thangue, A. Giordano, A. Graessmann, and M. Levrero. 1998. Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear translocation. Cancer Res. 58:1325.
26. Wang, S., R. Ghosh, and S. Chellappan. 1998. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol. Cell. Biol. 18:7487.
27. Dou, Q. P., B. An, K. Antoku, and D. E. Johnson. 1997. Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J. Cell. Biochem. 64:586.
28. Janicke, R. U., P. A. Walker, X. Y. Lin, and A. G. Porter. 1996. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J. 15:6969.
29. Cobrinik, D. 1996. Regulatory interactions among E2Fs and cell cycle proteins. Curr. Top. Microbiol. Immunol. 208:32.
30. Slansky, J. E., and P. J. Farnham. 1996. Introduction to the E2F family: protein structure and gene regulation. Curr. Top. Microbiol. Immunol. 208:1.
31. Bian, H., P. E. Harris, A. Mulder, and E. F. Reed. 1997. Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Hum. Immunol. 53:90.
32. Harris, P. E., H. Bian, and E. F. Reed. 1997. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J. Immunol. 159:5697.
33. Bian, H., P. E. Harris, and E. F. Reed. 1998. Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Int. Immunol. 10:1315.
34. Haruhito, A., and N. L. Tilney. 1994. Chronic graft rejection. Curr. Opin. Immunol. 6:770.
35. Paul, L. C., and B. Fellstrom. 1992. Chronic vascular rejection of the heart and kidney: have rational treatment options emerged? Transplantation 53:1169.
36. Skov, S. 1998. Intracellular signal transduction mediated by ligation of MHC class I molecules. Tissue Antigens 51:215.
37. Bregenholt, S., M. Ropke, S. Skov, and M. H. Claesson. 1996. Ligation of MHC class I molecules on peripheral blood T-lymphocytes induces new phenotypes and functions. J. Immunol. 157:993.
38. Woodle, E. S., D. M. Smith, J. A. Bluestone, W. M. I. Kirkman, D. R. Green, and E. W. Skowronrski. 1997. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J. Immunol. 158:2156.
39. Genestier, L., R. Paillot, N. Bonnefoy-Berard, G. Meffre, M. Flacher, D. Fevre, Y. J. Liu, P. Le Bouteiller, H. Waldman, V. H. Englehard, J. Banchereau, and J. P. Revillard. 1997. Fas-independent apoptosis of activated T cells induced by antibodies to the HLA class I a domain. Blood 90:3629.
40. Roosnek, E., A. Tunnacliffe, and A. Lanzavecchia. 1990. T-cell activation by a hispecific anti-CD3/anti major histocompatibility complex class I antibody. Eur. J. Immunol. 20:1393.
41. Geppert, T. D., L. S. Davis, H. Gur, M. C. Wacholtz, and P. E. Lipsky. 1990. Accessory signals involved in T-cell activation. Immunol. Rev. 117:5.
42. Wacholtz, M. C., S. S. Patel, and P. E. Lipsky. 1989. Patterns of costimulation of T-cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules. J. Immunol. 142:4201.
43. Geppert, T. D., and P. E. Lipsky. 1988. Activation of T lymphocytes by immobilized monoclonal antibodies to CD3: regulatory influences of monoclonal antibodies to additional T cell surface determinants. J. Clin. Invest. 81:1497.
44. Geppert, T. D., M. C. Wacholtz, L. S. Davis, and P. E. Lipsky. 1988. Activation of human T4 cells by cross-linking class I MHC molecules. J. Immunol. 140: 2155.
45. Hansen, N. Q., T. Tscherning, and M. H. Claesson. 1990. T-cell activation. IV. Evidence for a functional linkage between MHC class I, IL2 and IL4 receptor molecules. Cytokine 3:35.
46. Dissing, S., C. Geisler, B. Rubin, T. Plesner, and M. H. Claesson. 1990. T-cell activation. II. Activation of human T lymphoma cells by cross-linking of their MHC class 1 antigens. Cell. Immunol. 126:196.
47. Geppert, T. D., M. C. Walcholtz, S. S. Patel, E. Lightfoot, and P. E. Lipsky. 1989. Activation of human T-cell clones and Jurkat cells by cross-linking class I MHC molecules. J. Immunol. 142:3763.
48. Crawley, J. B., L. Rawlinson, F. V. Lali, T. H. Page, J. Saklatvala, and B. M. Foxwell. 1997. T cell proliferation in response to interleukins 2 and 7 requires p38 MAP kinase activation. J. Biol. Chem. 272:15023.
49. Lee, J. C., and P. R. Young. 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukocyte Biol. 59:152.
50. Kyriakis, J. M., and J. Avruch. 1996. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 18:567.
51. Morooka, T., and E. Nishida. 1998. Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells. J. Biol. Chem. 273:24285.
52. Nagata, Y., N. Takahashi, R. J. Davis, and K. Todokoro. 1998. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 92:1859.
53. Lukas, J., T. Herzinger, K. Hansen, M. C. Moroni, D. Resnitzky, K. Helin, S. I. Reed, and J. Bartek. 1997. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev. 11:1479.
54. 1-S transition. Mol. Cell. Biol. 18:141.
55. Zhao, X. M., T. K. Yeoh, M. Hiebert, W. H. Frist, and G. G. Miller. 1993. The expression of acidic fibroblast growth factor (heparin-binding growth factor-1) and cytokine genes in human cardiac allografts and T cells. Transplantation 56:1177.
56. Zhao, X. M., T. K. Yeoh, W. H. Frist, D. L. Porterfield, and G. G. Miller. 1994. Induction of acidic fibroblast growth factor and full-length platelet-derived growth factor expression in human cardiac allografts: analysis by PCR, in situ hybridization, and immunohistochemistry. Circulation 90:677.
57. Zhao, X. M., W. H. Frist, T. K. Yeoh, and G. G. Miller. 1994. Modification of alternative messenger RNA splicing of fibroblast growth factor receptors in human cardiac allografts during rejection. J. Clin. Invest. 94:992.
58. Kerby, J. D., D. J. Verran, K. L. Luo, Q. Ding, Y. Tagouri, G. A. Herrera, A. G. Diethelm, and J. A. Thompson. 1996. Immunolocalization of FGF-1 and receptors in human renal allograft vasculopathy associated with chronic rejection. Transplantation 62:467.
59. Fenoglio, J., E. Ho, E. Reed, E. Rose, C. Smith, K. Reemstma, C. Marboe, and N. Suciu-Foca. 1989. Anti-HLA antibodies and heart allograft survival. Transplant. Proc. 21:807.
60. Suciu-Foca, N., E. Reed, V. D. D'Agati, E. Ho, D. J. Cohen, A. I. Benvenisty, R. McCabe, J. M. Brensilver, D. W. King, and M. A. Hardy. 1991. Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 51:593.
61. Suciu-Foca, N., E. Reed, C. Marboe, P. Harris, P. X. Yu, Y. K. Sun, E. Ho, E. Rose, K. Reemtsma, and D. W. King. 1991. The role of anti-HLA antibodies in heart transplantation. Transplantation 51:716.
62. Ende, N., E. V. Orsi, N. Z. Baturay, and T. L. Britten. 1979. Properties of a cytotoxic kidney antibody associated with human renal transplantation. Am. J. Clin. Pathol. 71:543.
63. Duijvestijn, A. M., and P. J. van Breda Vriesman. 1991. Chronic renal allograft rejection: selective involvement of the glomerular endothelium in humoral immune reactivity and intravascular coagulation. Transplantation 52:195.
64. Cherry, R., H. Nielsen, E. Reed, K. Reemtsma, N. Suciu-Foca, and C. C. Marboe. 1992. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J. Heart Lung Transplant. 11:24.
65. Davenport, A., M. E. Younie, J. E. Parsons, and P. T. Klouda. 1994. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol. Dial. Transplant. 9:1315.
66. Costa, A. N., M. P. Scolari, S. Iannelli, A. Buscaroli, G. L. D'Arcangelo, B. Brando, F. Indiveri, M. Savi, L. C. Borgnino, L. B. DeSanctis, S. Stefoni, and V. Bonomini 1997. The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 63:167.
67. Reed, E. F., B. Hong, E. Ho, P. E. Harris, J. Weinberger, and N. Suciu-Foca. 1996. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation 61:566.
68. Zhang, Y., and S. P. Chellappan. 1996. Mol. Cell. Differ. 4:297.
69. Wang, S., N. Nath, A. Minden, and S. Chellappan. 1999. Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. EMBO J. 18:1559.